Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O9XO
|
||||
| Former ID |
DIB003312
|
||||
| Drug Name |
KH-902
|
||||
| Synonyms |
Fumintide; KH-902 (intravitreal, AMD/DME), Kanghong Biotechnologies
|
||||
| Indication | Diabetic macular edema [ICD9: 250, 362.01, 362.07, 362.53, 782.3; ICD10:E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9] | Phase 3 | [1] | ||
| Company |
Chengdu Kanghong Biotechnologies Co Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | VEGF receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01436864) A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD. U.S. National Institutes of Health. | ||||
| REF 2 | Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.